PART I GENERAL AIM ImmunoTech Inc. and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders for which there are inadequate or unmet therapies. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antivir...
Q2 FY2026 — expected 2026-07-28
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001493152-26-013301 | EDGAR | 84K words |
| 2025-03-27 | 2024-12-31 | 0001641172-25-000847 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001493152-24-012058 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010351 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001493152-22-008324 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001493152-21-007259 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001493152-20-005290 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001493152-19-004583 | EDGAR | — |
| 2018-03-30 | 2017-12-31 | 0001493152-18-004291 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001493152-17-003242 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-17 | 2025-09-30 | 0001493152-25-023894 | EDGAR | 37K words |
| 2025-08-14 | 2025-06-30 | 0001493152-25-011986 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-011033 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045971 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032355 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019917 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041294 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028610 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-016763 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-032118 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022600 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001493152-22-013341 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-06 | 0001493152-26-009190 | EDGAR | 21K words |
| 2026-02-05 | 0001493152-26-005208 | EDGAR | — |
| 2026-01-20 | 0001493152-26-002728 | EDGAR | — |
| 2026-01-12 | 0001493152-26-001898 | EDGAR | — |
| 2025-12-17 | 0001493152-25-028156 | EDGAR | — |
| 2025-11-19 | 0001493152-25-024156 | EDGAR | — |
| 2025-10-29 | 0001493152-25-020102 | EDGAR | — |
| 2025-10-20 | 0001493152-25-018583 | EDGAR | — |
| 2025-07-31 | 0001641172-25-021762 | EDGAR | — |
| 2025-07-28 | 0001493152-25-011441 | EDGAR | — |
364 total filings indexed. 332 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000946644 |
| Ticker | AIM |
| Exchange | NYSE |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.aimimmuno.com |
| Listed | 1995-11-02 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report